Advanced Solid News Today : Breaking News, Live Updates & To

Coherus Presents Preliminary Results from Phase I Dose

Published: May 23, 2024

CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective...

Source: globenewswire.com

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Published: April 24, 2024

REDWOOD CITY, Calif., April 24, 2024 -- Coherus BioSciences, Inc. today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the...

Source: marketscreener.com

Coherus Announces Presentation at the 2024 American Society

Published: April 24, 2024

REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of...

Source: globenewswire.com

Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024

Published: April 9, 2024

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.Encouraging VAXI...

Source: businessinsider.com

NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need

Published: January 9, 2024

Encouraging findings in heavily pretreated patients in multiple solid tumor indications, including MSS colorectal cancer , in ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4...